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Abstract
Galectin-4 is a carbohydrate-binding protein belonging to the galectin family. Here we provide novel evidence that galectin-
4 is selectively expressed and secreted by intestinal epithelial cells and binds potently to activated peripheral and mucosal
lamina propria T-cells at the CD3 epitope. The carbohydrate-dependent binding of galectin-4 at the CD3 epitope is fully
functional and inhibited T cell activation, cycling and expansion. Galectin-4 induced apoptosis of activated peripheral and
mucosal lamina propria T cells via calpain-, but not caspase-dependent, pathways. Providing further evidence for its
important role in regulating T cell function, galectin-4 blockade by antisense oligonucleotides reduced TNF-alpha inhibitor
induced T cell death. Furthermore, in T cells, galectin-4 reduced pro-inflammatory cytokine secretion including IL-17. In a
model of experimental colitis, galectin-4 ameliorated mucosal inflammation, induced apoptosis of mucosal T-cells and
decreased the secretion of pro-inflammatory cytokines. Our results show that galectin-4 plays a unique role in the intestine
and assign a novel role of this protein in controlling intestinal inflammation by a selective induction of T cell apoptosis and
cell cycle restriction. Conclusively, after defining its biological role, we propose Galectin-4 is a novel anti-inflammatory agent
that could be therapeutically effective in diseases with a disturbed T cell expansion and apoptosis such as inflammatory
bowel disease.
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Introduction
Although the pathogenesis of inflammatory bowel diseases
(IBD) is not fully understood, it is evident that both Crohn’s disease
(CD) and ulcerative colitis (UC) are linked to a failure of the
mucosal immune system and that both an unrestricted expansion
and an impaired apoptosis of T cells foster mucosal inflammation
[1,2]. Thus, therapeutic approaches inhibiting T cell proliferation
such as steroids, azathioprine/6-MP or calcineurin inhibitors or
drugs inducing T cell apoptosis such as tumor necrosis factor-a
antibodies are effectively used to treat CD and UC [3,4].
Galectins are a family of animal lectins defined by their
recognition of b-galactose and the presence of consensus amino
acid sequences [5]. They exhibit high levels of evolutionary
conservation in their carbohydrate-recognition domains (CRDs) of
about 130 amino acids responsible for carbohydrate binding. With
respect to the gastrointestinal (GI) tract, galectin-4 (Gal-4) is of
specific importance since RNAse protection assays have demon-
strated that it is expressed in gastrointestinal tissues, but not in
brain, kidney, skeletal muscle, heart, liver or lung tissue [6].
Since in human inflammatory disorders the ultimate goal is to
become inflammation-free, it will therefore be necessary to find a
therapeutic approach which not only blocks one or more
components of specific pro-inflammatory pathways, such as T
cell expansion and cytokine release, but also restores naturally
occurring anti-inflammatory systems, such as apoptosis, which
may be defective either in expression level or function in IBD.
Since galectins in general are able to inhibit inflammation and
induce apoptosis, we performed a step-by-step analysis of the effect
of gastrointestinal Gal-4 on human T cells responsible for
triggering inflammation and investigated the therapeutic effect of
Gal-4 in an animal model of experimental colitis.
Results
Expression of Gal-4 in T cells
Whereas it is known that in the porcine and murine small
intestine Gal-4 is expressed in epithelial cells [7], its expression
pattern in the human GI tract remains unknown. When the entire
human GI tract was sequentially characterized by immunohisto-
chemical staining, strong Gal-4 staining was observed in epithelial
cells of the antrum, ileum, colon and rectum (Fig. 1A) as well as in
the corpus, fundus, and jejunum (not shown). In contrast, only
weak Gal-4 positivity was detected in the underlying lamina
propria cells (Fig. 1A) and absent in liver and spleen (not shown).
Accordingly, Gal-4 mRNA expression in T cells was weak, but
detectable (Fig. 1B) using GAPDH as a house-keeping gene. When
the Gal-4 expression was quantified on the protein level, Gal-4 was
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activation status (Fig. 1C). Having defined that Gal-4 is strongly
expressed in gastrointestinal epithelial cells, we next investigated, if
Gal-4 is also secreted by epithelial cells and thus can interact with
the underlying T cells in the lamina propria.
Gal-4 secretion
To determine if Gal-4 is secreted by epithelial cells, HT-29, and
Caco-2 cells were cultured for 48 h after which Gal-4 secretion
was determined by a Gal-4 ELISA. Constantly, both cell lines
secreted within this timeline about 4566 pg/ml Gal-4. Having
defined that Gal-4 is secreted by epithelial cells, we next addressed
the question of whether Gal-4 binds to T cells, obligatory to
modulate their function.
Carbohydrate-dependent binding of Gal-4 to T cells
To investigate Gal-4 binding to T cells, Gal-4 was added to
resting and stimulated peripheral blood and lamina propria (LPT)
T cells and binding was quantified by flow cytometric analysis.
Gal-4 did not bind to unstimulated, but to anti-CD3 and anti-CD2
stimulated PBT and LPT, respectively. This binding was b-
galactoside-specifically, since the presence of 50 mM lactose as a
pan-galectin inhibitor significantly reduced its binding (Fig. 2A).
Sucrose tested at the same concentration failed to affect the
staining intensity in flow cytometry, excluding non-specific effects
(Fig. 2A). Next, we wanted to gain insight into the biochemical
nature of cell surface targets for Gal-4.
Gal-4 associates with CD3 but not with CD7 or b1-
integrin
We and others previously described that CD3, CD7, and
integrin-b1 have ligand capacity for Gal-1 and -2 [8,9]. Prior work
by Hokama et al. provided first evidence that Gal-4 interacts with
the immunological synapse [10], however the respective binding
region remained unclear. Thus, to scan the cell surface targets for
Gal-4 on T cells and specify the exact binding side, we performed
immunoprecipitation for Gal-4, followed by immunoblotting for
CD3, CD7, and integrin-b1. Similar to Gal-1, but in contrast to
Gal-2, CD3 was detected after affinity fractionation of extract with
immobilized Gal-4 (Fig. 2B). In contrast to Gal-1 and -2, no trace
of b1-integrin or CD7 was detected (not shown). A BSA control
ascertained the absence of non-specific protein-protein interac-
tions (Fig. 2B). Gal-1 served as a positive control (Fig. 2B), since it
known that it bind at the CD3 receptor complex [9]. The CD3
receptor complex is required for cell-surface expression of the
antigen-binding chains and signaling. Having demonstrated that
Gal-4 homes in on CD3 or a tightly associated glycoprotein as
major target, we hypothesized that Gal-4 modulates central T cell
functions and went on to investigate the effect of Gal-4 on T cell
activation and proliferation.
Gal-4 inhibits T cell activation and proliferation
Activation by costimulatory molecules is required to fully
stimulate T cells and avoid anergy [11]. To determine T cell
activation and proliferation, PBMC were activated with plate-
bound CD3 mAb and incubated at the same time with or without
100 mg/ml Gal-4. Dead cells were excluded for further cell cycle
analysis by proper gating on the respective DNA content. As
demonstrated by flow cytometry analysis, Gal-4 significantly
inhibited expression of the co-stimulatory molecules CD80 and
CD86 expression on PBMC (Fig. 3A). Correspondingly, expres-
sion of IL-2 receptor-a chain (CD25), a sensitive marker for T cell
activation and post-translational protein phosphorylation, deter-
mined by p-Tyr western blotting, were significantly down-
regulated in Gal-4 co-cultured PBT (not shown). Of note,
100 mg/ml Gal-4 did not activate T cells in the absence of
concurrent CD3 stimulation (not shown). T cell activation initiates
cell cycling, a complexly regulated movement through different
phases. Thus, we tested the effect of Gal-4 on PBT cell cycling
separately for every cell cycle phase. The analysis of cyclin A,
regulating the S-phase, and cyclin B1, propelling the cells from late
G2 to mitosis, was measured in conjunction with propidium iodide
(PI) staining to exactly localize its increase within the cell cycle and
to exclude dead cells. The analysis revealed that Gal-4 potently
inhibited T cell cycling (Fig. 3B and C). Additional BrdU-staining
revealed that Gal-4 did not kill cells at a specific point in the cell
cycle (not shown).
Figure 1. Identification of Galectin-4 expression. (A) Gal-4
expression was detected in cryosections of the GI tract of healthy
volunteers. The results are representative for four individuals (original
magnifications: 6100). (B) PCR analysis of Gal-4 mRNA expression in
resting and anti-CD3/CD28 stimulated PBT. (C) Flow cytometric analysis
of intra- and extracellular Gal-4 content in resting and anti-CD3/CD28
stimulated PBT. Data are representative of three individual experiments.
doi:10.1371/journal.pone.0002629.g001
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did not significantly differ in control and Gal-4 co-cultured
activated T cells (not shown). Galectins are present intracellular,
but can also be secreted [12] thus, we next aimed to compare the
function of extracellular and intracellular Gal-4 on T cells.
Therefore, we down-regulated Gal-4 expression with specific
antisense oligonucleotides. As verified by TaqMan real time PCR,
Gal-4 expression was inhibited by the specific antisense oligonu-
cleotides by 4967%. Interestingly, in contrast to extracellular Gal-
4 addition, Gal-4-blockade had no impact on cyclin B1 expression
(Fig. 3D).
The final goal of T cell cycling is to clonally expand the cell
population necessary to provide a sufficient adaptive immune
response. As determined by CFDA staining, after four days of
stimulation with anti-CD3/CD28 mAb three T cell daughter
populations were detected. In contrast, after equal stimulation of T
cells in the presence of Gal-4 only one daughter cell population
was detected (Fig. 3E). So far, we demonstrated on multiple levels,
that Gal-4 potently inhibits T cell activation and consequently T
cell cycling and expansion. We went on to determine the effect of
Gal-4 on T cell cytokine secretion.
Modulation of cytokine secretion in stimulated PBT and
LPT by Gal-4
The release of cytokines is crucial for the differentiation of T
cells [13]. Having demonstrated that Gal-4 substantially inhibits
PBT cell cycling, we were interested in whether Gal-4 modulate
cytokine release patterns in T cells. PBT were isolated and
stimulated with anti-CD3/CD28 mAb in the presence or absence
of Gal-4 for 72 hours. As determined by CBA analysis, Gal-4
potently reduced TNF-a, IL-6, -8 and -10 secretion (p,0.01)
(Fig. 4A). Using the same experimental design as above, we
transfected PBT with specific Gal-4 antisense to investigate the
role of endogenous Gal-4. Gal-4 expression was inhibited by
4967%. Interestingly, in contrast to the lack of Gal-4 antisense to
interfere with the T cell cycle, blockade of Gal-4 expression
increased TNF-a secretion of activated T cells by 86.069% and
IL-6 secretion by 23.063%. Next, we investigated the effect of
Gal-4 on the cytokine secretion profile of CD2-stimulated LPT.
Comparable to PBT, Gal-4 reduced the secretion of TNF-a by
1863%, IL-6 by 2261.5%, IL-8 by 1162.8% and IL-10 by
762%, respectively. Furthermore, when PBT were activated by
anti-CD3 and LPT by anti-CD2 and cultured for 48 h IL-17
Figure 2. Galectin-4 binds to stimulated, but not resting T cells. (A) Flow cytometric analysis of Gal-4 binding to resting and anti-CD3/CD28
stimulated T cells using Gal-4 detected by an anti-Gal-4 Ab and PE-labeled secondary Ab. Carbohydrate-dependence of the binding was analysed by
addition of 50 mM lactose as a pan-galectin inhibitor and 50 mM sucrose as control. Data are representative of three individual experiments. (B)
Immunoprecipitation of Gal-4 binding complexes. BSA served as negative, Gal-1 as positive control. Data are representative for four individual
experiments.
doi:10.1371/journal.pone.0002629.g002
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2062.5% and 2963%, respectively (Fig. 4B). We further
performed a TNF-a secretion assay based only on living cells. T
cells were stimulated for 48 h with anti-CD3/CD28 mAb in the
presence or absence of 100 mg/ml Gal-4. After restimulation with
PMA (phorbol 12-myristate 13-acetate) and ionomycin, the
secreted TNF-a was bound to the surface of the secreting cells,
stained and detected by flow cytometry. In addition, T cells were
stained with PI to exclude dead cells for further analysis. The
respective results (not shown) were comparable to the results
depicted in figure 4.
Having described the cell-binding capacity of Gal-4 and its
ability to modulate T cell activation, cycling and expansion as well
as cytokine secretion, we next addressed the question of whether its
cell binding induces apoptosis.
Induction of T cell apoptosis by Gal-4
Using the externalization of phosphatidylserine as a marker of
cell apoptosis and positive DNA staining as an indication of
membrane leakage, we tested the ability of Gal-4 to induce PBT
and LPT cell death. As depicted in figure 5A, Gal-4 induced dose-
dependently apoptosis of activated PBT and LPT, but not resting
T cells. In contrast to its strong induction of T cell apoptosis, T cell
necrosis, as verified by PI staining, was not induced by Gal-4
(Fig. 5B). Having verified the strong capacity of Gal-4 to induce T
Figure 3. Galectin-4 inhibits activation, cell cycle progression,
and expansion of activated T cells. (A) PBMC were stimulated with
anti-CD3 and cultured for 72 h in the presence or absence of 100 mg/ml
Gal-4. CD80 and CD86 positive cells were detected by flow cytometric
analysis. Data represent mean6SEM of three individual experiments.
*p#0.05 for decrease vs. baseline. (B) Flow cytometric analysis of cyclin-
A expression of anti-CD3/CD28 stimulated T cells cultured in the
presence or absence of 100 mg/ml Gal-4. Data are representative for
four individual experiments. (C) Flow cytometric analysis of cell cycle
progression and cyclin-B1 expression of anti-CD3/CD28 stimulated T
cells cultured in the presence or absence of 100 mg/ml Gal-4. Data are
representative for four individual experiments. (D) PBT were transfected
with Gal-4 siRNA or scrambled control. After stimulation with IL-2 cell
cycle progression and cyclin B1 expression were determined. Data are
representative of three individual experiments. (E) Anti-CD3/CD28
activated PBT were stained with CFDA and T cell expansion was
determined after four days of incubation in the presence or absence of
100 mg/ml Gal-4 by flow cytometric analysis. Data are representative of
three individual experiments.
doi:10.1371/journal.pone.0002629.g003
Figure 4. Galectin-4 and its domains distinctively reduce
secretion of pro-inflammatory cytokines. (A) Cytokine release
was tested in PBT stimulated with anti-CD3/CD28 for 72 hours. Data
represent mean6SEM of six individual experiments. *p#0.01 for
decrease vs. baseline. (B) IL-17 secretion of LPT and PBT was determined
by an IL-17 specific ELISA. LPT and PBT were activated by anti-CD2 or -
CD3/CD28 mAb, respectively and cultured in the presence or absence
of 100 mg/ml Gal-4. Data represent mean6SEM of three individual
experiments.
doi:10.1371/journal.pone.0002629.g004
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PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2629Figure 5. Galectin-4 induces T cell apoptosis caspase-independently via calpain-mediated pathways. (A) PBT and LPT were stimulated
with anti-CD3/CD28 or -CD2, respectively, in the presence of 0, 50, 100 or 200 mg/ml Gal-4 and apoptosis was determined by annexin-V staining. Data
represent mean6SEM of eight individual experiments. *p#0.05 for increase vs. baseline. (B) PBT were stimulated in the presence of 0, 25, 50, 100 or
200 mg/ml Gal-4. Apoptosis was detected by annexin V/PI staining, necrosis by PI staining followed by flow cytometry. Data represent mean6SEM of
six individual experiments. *p#0.05 for increase vs. baseline. (C) PBT were transfected with Gal-4 siRNA or scrambled control, activated by anti-CD3/
Gal-4 and Mucosal Inflammation
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involved in apoptosis regulation. Indeed, blockade of Gal-4
expression by specific antisense oligonucleotides modestly reduced
adalimumab-induced T cell death from 63% of cells to 53%
(Fig 5C).
Since 50 mM lactose was effective in impairing binding of Gal-4
to T cells, we reasoned that cell viability should remain unaffected
when blocking carbohydrate-dependent binding. This was indeed
the case in Gal-4, while sucrose presence proved inert (not shown).
Furthermore, treatment with 10 nM and 1 mM cycloheximide did
not inhibit Gal-4 induced T cell apoptosis, indicating that
abolishment of de novo protein synthesis is not required for its
proapoptotic activity (not shown). Having excluded the need for
protein synthesis to induce T cell death, we next aimed to
investigate the pathways by which Gal-4 causes T cell death.
Gal-4-mediated induction of T-cell apoptosis is caspases-
independent but calpain-dependent
Caspases are central initiators and executors of T cell apoptosis
and we previously demonstrated that Gal-2 induces T cell death
via caspase-3 and -9 signaling [9]. We thus investigated caspases-3,
-8 and -9 activity in Gal-4 treated anti-CD3/CD28 stimulated
PBT using fluorogenic substrate assays. As depicted in figure 5D,
neither the activity of the up-stream caspases-8 or -9, nor the
activity of the central executor caspases-3 was induced by 100 mg/
ml Gal-4, a dose sufficient to induce T cell apoptosis (Fig. 5B).
Accordingly, the pan-caspase inhibitor zVAD-fmk (50 mM) and
the caspases-3 inhibitor zDEVD-fmk (50 mM) failed to prevent
Gal-4 induced apoptosis of activated T cells (not shown).
Consequently, we went on to investigate caspase-independent
apoptotic pathways [14]. Calpains are a family of calcium-
dependent thiol-proteases that induce apoptosis caspase-indepen-
dently by proteolyzing a wide variety of cytoskeletal, membrane-
associated and regulatory proteins [15]. Indeed, the irreversible
calpain-inhibitor Z-LLY-fmk inhibited Gal-4 induced T cell
apoptosis by 60% (Fig. 5E). Aiming to independently confirm
the role of calpain signaling, we inhibited extra- and intracellular
calcium levels by the Ca
2+-chelators EGTA and BAPTA-AM. As
depicted in figure 5E, both inhibitors were able to sufficiently
block Gal-4 induced T cell apoptosis, indicating that a preceding
Ca
2+ mobilization is required for Gal-4 to induce T cell death.
Accordingly, and confirming the participation of the mitochon-
drial signaling pathway in Gal-4 mediated T cell death
independently, we could demonstrate by rhodamine123 staining
that Gal-4 and strongly reduces the Dy (Fig. 5F and G). To
determine if the reduction of the mitochondrial membrane
potential was an initiating event we performed a time kinetic
and checked the mitochondrial membrane potential 3, 6, 12, 24
and 48 h after incubation with 100 mg/ml Gal-4. As depicted in
figure 5F the mitochondrial membrane potential was already
diminished 3 h after incubation with Gal-4 and decreased more
12 h after incubation (Fig 5G). The time kinetic showed a
continuous decrease of the mitochondrial membrane potential up
to 7264% of cells 48 h after Gal-4 incubation (not shown).
The results so far demonstrated that Gal-4 potently inhibits T
cell activation, pro-inflammatory cytokine secretion, and induces
T cell apoptosis. In IBD, T cell activation is increased and
apoptosis impaired, making Gal-4 an attractive candidate to limit
mucosal inflammation. Thus, we went on to evaluate the effect of
Gal-4 in a well-established model of experimental colitis.
Gal-4 ameliorates DSS-induced colitis and induces
apoptosis of mucosal mononuclear cells
Acute colitis was induced in Balb/c mice by administration of
5% DSS in the drinking water. The animals were treated either
with sterile saline as controls or 1 mg Gal-4/kg BW for 8 days i.p.
three times daily until they were sacrificed on day 8. As evaluated
with the well-known Rachmilewitz disease activity index (DAI)
[16,17], mice exposed to 5% DSS and treated with sterile saline
developed symptoms of acute colitis with diarrhea first, followed
by rectal bleeding and substantial weight loss (not shown). In
contrast, when mice with DSS-induced colitis were treated with
Gal-4, the DAI dropped significantly from 3.960.4 to 1.660.3
compared to control animals (p , 0.01) (Fig. 6A). Consistent with
the results of body weight and DAI scores histological assessment
of colonic tissues using the well-established Dieleman score [18],
previously described by Cooper [19], revealed that the colons from
Gal-4 treated mice displayed significantly reduced mucosal
damage and facilitated mucosal repair compared to control mice
(not shown). The distinct modulation of the disease activity index
and histological damage was also confirmed by a significant
reduction of MPO activity in the colonic mucosa of Gal-4 treated
mice compared to control animals (p , 0.05) and increased colon
length (not shown). Induction of mucosal T cell apoptosis is a
highly efficient therapeutic approach [20] and since we demon-
strated that Gal-4 induces T cell apoptosis in vitro, we next asked if
Gal-4 exerts its therapeutic effect by inducing mucosal apoptosis in
vivo. By using TUNEL (terminal deoxynucleotidyltransferase-
mediated UTP end labeling) staining as a well established method
for detecting DNA fragmentation, we could show that Gal-4
treatment robustly increased apoptosis of mucosal mononuclear
cells (24.862.1%), whereas in control animals only few apoptotic
cells were detected (561.8%) (Fig. 6B, C). As previously discussed,
in IBD unrestricted T cell proliferation results in mucosal
inflammation, making it desirable to inhibit T cell cycling in
mucosal inflammation. Using in situ BrdU labeling, we could
demonstrate, that in response to DSS application, BrdU is found
within the epithelial, but also sub-epithelial compartment but,
congruently with the in vitro results, cell expansion in Gal-4 treated
animals was clearly inhibited, again confirming the applicability of
this colitis model and the transmissibility of the in vitro data to the in
vivo model (Fig 6D, E). During acute inflammation a wide range of
cytokines influence cell activation, cell adhesion and recruitment of
leukocytes such as monocytes, lymphocytes and neutrophils. Thus,
to complete the picture, we measured the ability of Gal-4 to
modulate cytokine secretion in this model of intestinal inflamma-
tion.
CD28 and cultured in the presence of the TNF-a blocker adalimumab for three days. Apoptosis was detected by annexin V/PI staining followed by
flow cytometry. Data are representative for three individual experiments. (D) Caspase-3, -8, and -9 activity in anti-CD3/CD28 stimulated T cells
cultured in the presence or absence of 100 mg/ml Gal-4. Data are representative for three individual experiments. (E) PBT were activated by anti-CD3/
CD28 and cultured for 24 h in the presence or absence of 100 mg/ml Gal-4 and 50 mM Calpain inhibitor z-LLY-fmk, 4 mM EGTA or 30 mM BAPTA-AM.
Data are representative for three individual experiments. (F) Disruption of the mitochondrial membrane potential was detected by rhodamine123
staining followed by flow cytometric analysis. T cells were stimulated with anti-CD3/CD28 and incubated for 3 h in the presence or absence of
100 mg/ml Gal-4. Afterwards cells were analysed by flow cytometry. All data are representative for three individual experiments. (G) Disruption of the
mitochondrial membrane potential was detected after 12 h by rhodamine123 staining followed by flow cytometric analysis. All data are
representative for three individual experiments.
doi:10.1371/journal.pone.0002629.g005
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PLoS ONE | www.plosone.org 6 July 2008 | Volume 3 | Issue 7 | e2629Figure 6. Galectin-4 ameliorates experimental colitis by inducing apoptosis and reduction of pro-inflammatory cytokine secretion.
(A) Disease activity index in acute DSS-induced colitis, treated with 0.9% sterile saline (control) or 1 mg/kg BW Gal-4 i.p. three times daily. *p#0.01 for
change vs. control. (B) Detection of apoptotic cells by TUNEL staining in cryosections of colonic tissue from mice with experimental colitis treated
with 0.9% sterile saline (control) or 1 mg/kg BW Gal-4 i.p. three times daily. (C) Apoptotic cells after TUNEL staining were counted in three power
fields on four slices of different animals by an investigator blinded to the protocol. *p#0.05 for change vs. control. (D) Detection of proliferating cells
by BrdU staining in cryosections of colonic tissue from mice with experimental colitis treated with 0.9% sterile saline (control) or 1 mg/kg BW Gal-4
i.p. three times daily. (E) BrdU positive cells were counted in three power fields on four slices of different animals by an investigator blinded to the
protocol. *p#0.01 for change vs. control. (F) Cytokine secretion was determined by CBA analysis from colonic cultures from mice with experimental
colitis treated with 0.9% sterile saline (control) or 1 mg/kg BW Gal-4 i.p. three times daily. All data represent mean6SEM of ten individual
experiments. *p#0.05 for change vs. control.
doi:10.1371/journal.pone.0002629.g006
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secretion
In parallel to the in vitro experiments, we first examined cytokine
secretion of PBMC, isolated from control and Gal-4 treated
animals after three days of additional activation with anti-CD3
mAb. By using CBA assays, we demonstrated that Gal-4 reduced
the secretion of the pro-inflammatory cytokine TNF-a by
2163.8%, while the release of IFN-c was not altered (not shown).
With regard to anti-inflammatory cytokines, Gal-4 increased IL-10
secretion by 2962% compared to controls (not shown). Finally, we
measured mucosal cell cytokine secretion in our model by using
the colon culture system [21]. As depicted in figure 6F, compared
to controls, Gal-4 treatment reduced TNF-a secretion by
4066.4% (p , 0.05), increased IL-10 secretion by 40069.6% (p
, 0.01), while IFN-c secretion was not changed.
Discussion
Due to growing scientific evidence, the important role of
galectins as central regulators of immune and inflammatory
responses is undisputable [5]. Nevertheless, little information is
available about the functional role of galectins during mucosal
inflammation, where a disturbed innate and adaptive immune
system triggers local and systemic inflammation.
Gal-1 is so far the best investigated member of the galectin
family and Santucci and coworkers demonstrated that the proto-
type galectin Gal-1 suppresses experimental colitis [22]. However,
Gal-1 is constitutively expressed in most organs [5], showing that
Gal-1 broadly, but also nonspecifically, interact with the immune
system. In contrast, the tandem-repeat type Gal-4 is exclusively
expressed within the GI tract which suggests that Gal-4 might play
a more defined and selective role within the intestinal mucosa,
prompting us to investigate the role of Gal-4 in mucosal
inflammatory processes.
By performing sequential immunohistochemical analysis, we
showed strong Gal-4 expression in epithelial cells along the
alimentary tract and thus confirmed the previously described RNA
expression profile [7]. Additionally, we demonstrated that Gal-4 is
secreted by intestinal epithelial cell lines, a pre-requirement to
interact with the underlying cells of the lamina propria. T cell
dysfunction is undoubtedly a key feature in the initiation and
perpetuation of IBD and by demonstrating that Gal-4 binds to
activated peripheral and mucosal T cells, we set ground to further
investigate the role of Gal-4 in the adaptive immune system.
Interestingly, our finding that Gal-4 binds only to activated, but
not resting T cells, might explain the recently described
phenomena by Hokama et al., that the reactivity of CD4+ T
cells to Gal-4 is only elicited under inflammatory conditions [10].
The selective binding patterns of Gal-4 suggested that Gal-4
binding sides might be associated with surface regions involved in
the activation of T cells and in deed, Hokama et al. reported that
Gal-4 binds to CD4+ T cells at the immunological synapse [10].
We could now confirm this finding and demonstrated, that Gal-4
homes in on the CD3 region, and thus provide evidence that not
only the prototype galectins [8], but also the tandem-repeat
galectins associate with this receptor complex.
The CD3 receptor complex is required for cell-surface
expression of the antigen-binding chains, T cell signaling and
activation. Thus, the binding of extracellular Gal-4 to this complex
or a tightly associated glycoprotein as major target implies that
Gal-4 is capable of modulating central T cell functions. The strong
down-regulation of CD25 expression of CD3-activated T cells by
Gal-4 proves the biological consequence of the Gal-4 binding to
the CD3 complex. Performing a detailed analysis of essential cell
cycle checkpoints, we revealed that the restricted activation of T
cells by Gal-4 is carried through the whole cell cycle and finally
results in a declined mitosis and expansion of the respective T cell
population. Proving the concept that the binding of extracellular
Gal-4 is linked to the capacity of Gal-4 to inhibit cell cycling,
blockade of endogenous Gal-4, which is not linked to the CD3
complex, failed to modulate T cell cycling.
T cell cycling and cytokine secretion are ultimately linked [13].
Adding evidence to this association, Gal-4 potently reduced TNF-a,
IL-6, -8, -10, and -17 secretion. Although TNF-a serum and mucosa
levelsseemtobevariableinIBD[23,24],itiswellrecognizedthatthis
cytokine plays a crucial role in the pathogenesis of IBD and its
blocking is effective in the therapy of IBD [23,25]. With regard to IL-
6, a broad spectrum cytokine with characteristics of an acute-phase
reactant, mucosal cytokine levels are elevated consistently in IBD
tissues and neutralization of soluble IL-6 receptors in vivo causes
suppression of colitis activity and induction of apoptosis [26].
Interestingly, it was recently demonstrated by Hokama et al. that
Gal-4 increases IL-6 secretion in CD4
+ T cells isolated from TCR-a
knockout mice with a unique subset (TCRa
2b
+), but not in CD4
+ T
cells from wild-type mice, confirming the association of Gal-4 to the
TCR region and indicating that the ability of CD4
+ Tc e l l st o
produce IL-6 in response to Gal-4 is dependent on the presence of
TCR mutations [10].
The idea that Gal-4 might restore naturally occurring anti-
inflammatory systems which are defective in IBD was substanti-
ated by our observation that Gal-4 potently induces PBT, but also
LPT apoptosis. Having said so, it was now crucial to investigate if
in reverse blockade of endogenous Gal-4 is capable to reduce T
cell death. Uncovering the involvement of Gal-4 in the apoptotic
program of T cells and assigning a new biological role to
endogenous Gal-4, in deed, inhibition of Gal-4 expression by
specific antisense oligonucleotides decreased TNF-a inhibitor
induced T cell apoptosis substantially.
The potency of galectins to induce T cell apoptosis is common to
the prototype and the chimera type galectins, however, the
underlining pathways are distinct. Whereas Gal-1 induces PBMC
apoptosis via caspase activation [9,27], Hahn et al. reported, that T
cell death induced by Gal-1 in MOLT-4 is mediated caspase-
independently [28]. Recently, Stowell and coworkers reported that
human Gal-1, -2, and -4 induce death of neutrophil granulocytes,
but failed to induce cell death in the leukemic cell lines MOLT-4
and HL-6 [29]. However, both cells lines have disabled apoptotic
programs [30], incongruous to directly compare the results.
Furthermore, however speculative, the deletion within the TCR-a
locus of MOLT-4 [31], might contribute to the described resistance
of MOLT-4 towards Gal-4 induced cell death. Although Gal-4
induces T cell death carbohydrate-dependent without need of de
novo protein synthesis, a feature shared with Gal-1, Gal-2 and Gal-9
[9,15,28], Gal-4 neither activated caspase activity nor was its pro-
apoptotic effect blocked by caspase inhibitors. Our study now
provided further evidence that galectins distinctively induce T cell
apoptosis and that both, caspase-dependent and caspase-indepen-
dent death pathways can be initiated by galectins. In deed, we
identified calcium-calpain signaling as a crucial pathway by which
Gal-4 induces T cell death. This trail is shared with the tandem-
repeat-type galectin-9, but not Gal-2 [9], adding to the evidence
that the galectins investigated so far, despite the common
carbohydrate binding to T cells, all induce T cell death distinctively.
In IBD, T cell activation is increased and apoptosis impaired,
making Gal-4 an attractive candidate to potentially limit mucosal
inflammation.Thus, wewent onand evaluatedthe effectofGal-4in
a well-established model of experimental colitis [32]. When colitis
was induced in mice by DSS application, Gal-4 treatment
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histopathological signs of mucosal inflammation. The correspond-
ing decrease in neutrophil infiltration and reduced MPO activity in
the intestinal mucosa further confirmed the biological relevance of
this finding. Despite current discussion, it is well accepted that
reasoned by the fact that mucosal T cell apoptosis is impaired in
IBD [33], the induction of mucosal T cell death is a highly efficient
approach in the treatment of both CD and UC [20]. Thus, the
induction of apoptosis of mucosal cells by Gal-4 not only translates
the in vitro results to the in vivo situation, but also explains the
therapeutic effect of Gal-4 in experimental colitis. Mucosal
inflammation is initiated and perpetuated by the secretion of pro-
inflammatory and chemotactic cytokines and potent anti-inflam-
matory drugs are able to inhibit their release [34,35]. Thus, the
potent down-regulation of peripheral and also mucosal TNF-a and
IL-10 secretion by Gal-4 underscores the potential therapeutic use
of Gal-4 and explains its beneficial effect in experimental colitis.
Our results systematically and sequentially uncovered the
expression and secretion profile of Gal-4 as well as a previously
unrecognized biological function of this lectin. We could
demonstrate that Gal-4 potently binds to activated T cells at the
CD3 region which is translated in a potent inhibition of cell cycle
progression and induction of antigen-induced cell death. By
ameliorating experimental colitis via induction of mucosal T cell
apoptosis and the potent inhibition of pro-inflammatory cytokine
release, we identified gastrointestinal Gal-4 as a potential novel
candidate to treat mucosal inflammation.
Materials and Methods
Isolation and culture of T cells
PBMC were isolated from peripheral blood samples, lamina
propria T cells (LPMC) from surgical specimen, essentially as
previously described [9,36]. Signed informed consent was
obtained from each subject. Approval of the protocol and consent
form was granted by the local ethics committee of the Charite ´
(Berlin, Germany). For isolation of T cells specific magnetic cell
sorting (Miltenyi Biotech) was performed negatively selecting the
CD3
+ population. Cells were cultured in RPMI 1640, containing
10% fetal calf serum, 1.5% HEPES buffer, 2.5% penicillin-
streptomycin and stimulated with plate-bound anti-CD3 mAb
(clone OKT3; kindly provided by Janssen-Cilag, Neuss, Germany)
and anti-CD28 mAb (ANC28.1/5D10; Ancell Corp.), LPT with
anti-CD2 (T112 and T113; generously provided by Ellis Reinherz,
Dana Farber Cancer Institute, Boston, MA). T cells were cultured
for 24, 48 or 72 h in the presence or absence of 100 mg/ml Gal-4
(R&D Systems).
Immunohistochemistry for Gal-4 expression
Immunohistochemical staining was performed using biopsies
from human colonic tissue of healthy volunteers. Patients
underwent colonoscopy for gastrointestinal symptoms such as
abdominal pain or changed stool habits. Histological examination
of the control subjects showed no inflammation. Signed informed
consent was obtained from each subject. Approval of the protocol
and consent form was granted by the local ethics committee of the
Charite ´ (Berlin, Germany). Expression of Gal-4 was revealed using
a goat anti-human Gal-4 polyclonal Ab (R&D Systems) followed by
a biotinylated anti-goat-Ab (Vector laboratories). Negative controls
were incubated with the biotinylated anti-goat-Ab only. Complexes
were uncovered by adding avidin-biotinylated enzyme complex to
all sections in the presence of 3-amino-9-ethylcarbazole (AEC)
(Vector laboratories). Nuclear staining with hematoxylin (HE) was
performed subsequently. The slides were studied in Axioskop (Zeiss)
digital photographs were taken with Axiocam (Zeiss).
Galectin-4 secretion
Levels of Gal-4 were determined in supernatants of HT-29 and
Caco-2 cells cultured for 48 h. Gal-4 was detected by ELISA using
an anti-human Galectin-4 capture Ab (R&D Systems) and a
biotinylated anti-human Galectin-4 Ab (R&D Systems) and
visualized by streptavidin-horseradish peroxidase and TMB
substrate (both from BD Pharmingen).
Galectin-4 binding to T cells
Determination of Gal-4 binding to T cells was performed by
incubating resting and for 48 h CD3/CD28-stimulated PBT and
CD2-stimulated LPT with 5 mg/ml Gal-4, a dose not able to
induce T cell apoptosis. Binding was detected 24 h after
incubating cells with Gal-4 by a goat anti-human Gal-4 polyclonal
Ab followed by staining with PE-labeled secondary Ab (BD
Pharmingen) followed by flow cytometric analysis. Carbohydrate-
dependence of the binding was analysed by addition of 50 mM
lactose as a pan-galectin inhibitor and 50 mM sucrose as control.
Polymerase chain reaction
Total RNA was isolated using RNA Bee RNA isolation solvent
(Tel-Test Inc.). 2.5 mg of total RNA were reverse transcribed and
Gal-4-specific mRNA was amplified using the following primers:
sense 59-TGGTAAATGGAAATCCCTTCTATG-39, antisense
59-GAGCTGTGAGCCCTCCTT-39 (Tib Molbiol, Berlin, Ger-
many). The thermal commenced with a hot start at 94uC for
4 min, followed by 40 cycles each consisting of 94uC for 45 s,
annealing for 45 s at 58uC, and extension at 72uC for 60 s, and
terminated after a final 10-min period at 72uC. The products were
separated on a 1.5% Tris-acetate/EDTA agarose gel and
visualized by ethidium bromide staining under UV light.
Transfection of siRNA
For transfection, 5610
6 PBMC were resuspended in an
optimized transfection solution for primary human T cells
(Amaxa). Each sample was transfected with between 0.5 and
10 mM siRNA, according to the optimized protocol for unstimu-
lated human T cells (Amaxa). For Gal-4 silencing a siRNA target
pool was used (Dharmacon RNA Technologies), the scrambled
control was a non-targeting pool (Dharmacon RNA Technolo-
gies). 12 hours after transfection cells were stimulated with IL-2
and cultured in the presence or absence of 100 mg/ml Gal-4 with
and without 50 mg/ml adalimumab. Cells were harvested and
analysed by flow cytometry 48 h post-transfection. Following
isolation of total RNA with RNA Bee, the efficacy of the specific
siRNA to downregulate Gal-4 mRNA expression was determined
by a TaqMan real-time PCR on a MxPro 3000 (Stratagene, CA)
and quantified with SybrHGreen (Applied Biosystems). GAPDH
was used to normalize total RNA.
Magnetic separation of Gal-4-containing complexes
For separation of Gal-4-associated complexes, tosyl-activated
supermagnetic polystyrene beads (Dynalbeads; Dynal Biotech) were
coated with BSA, Gal-1 (R&D Systems) and Gal-4. After incubation,
the beads were washed, blocked in 0.2 M Tris buffer (pH 8.5
containing 0.1% BSA) and incubated with PBT. Free cells were
removed by washing, and cells bound to the beads were treated with
lysis buffer (20 mM Tris-HCl, pH 7.6, 10 mM MgCl2, 0.05%
Triton X-100, and 50 mM phosphatase and protease inhibitor
mixtures). The extract was subjected to SDS-PAGE electrophoresis.
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Cells were lysed in cell lysis buffer (1% Triton X-100, 0.5%
Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, 5 mM
EDTA, 50 mM protease and phosphatase inhibitor mixtures,
1 mM PMSF, 100 mg/ml trypsin-chymotrypsin inhibitor, and
100 mg/ml chymostatin in PBS). 10 mg of each sample were
fractionated on a 4-12% tris-glycine gel and transferred to a
0.2 mm nitrocellulose membrane (Invitrogen Life Technologies).
The primary and the appropriate HRP-conjugated secondary Ab
were purchased from Santa Cruz Biotechnology.
Flow cytometric analyses
T cells were analysed by flow cytometry as previously described
[9] using a flow cytometer (FACSCalibur; Beckman Coulter). To
perform analysis of intracellular proteins, cells were fixed in
paraformaldehyde and permeabilized by PBS containing 0.5%
saponin (Sigma-Aldrich). Cyclin A-PE, Cyclin B1-PE, PE-labeled
anti-active caspase 3, CD3-PE, CD4-PE, CD4-FITC, CD25-
FITC, CD80-PE, CD86-PE and annexin V FITC were purchased
from BD Pharmingen, PI from Calbiochem.
Analysis of T cell cycling and division
PBMC were activated with plate-bound CD3 mAb and
incubated in the presence or absence of 100 mg/ml Gal-4 for
72 h. Staining for DNA content and cyclin B1 follwed by flow
cytometry analysis was performed, as described previously [37].
Dead cells were excluded for further cell cycle analysis by proper
gating on cells with diploid DNA content. Analysis of cell kinetics
with BrdU staining was performed as previously described [37]. In
brief, cells were incubated with 25 mg/ml BrdU chased with
thymidine. BrdU labeled DNA was stained with anti-BrdU (BD
Pharmingen) and PI following denaturation of DNA by acid
treatment and analysed by flow cytometry. Analysis of cell division
by dye dilution was performed using the Vybrant CFDA SE Cell
Tracer Kit (Molecular Probes). Cells were resuspended in PBS
with 5 mM carboxyfluorescein diacetate succinimidyl ester (CFDA
SE) per 10
6 cells. After staining, the cells were cultured alone
(unstimulated) or in the presence of plate-bound anti-CD3 mAb,
CD28 and IL-2 (20 U/ml). After 4 days, the cells were analysed by
flow cytometry.
Analysis of cytokine secretion
To determine cytokine secretion, human PBT were activated by
anti-CD3 and anti-CD28 mAb, murine PBMC were activated by
anti-murine CD3 (clone 145-2C11; BD Pharmingen; 10 mg/ml)
mAbs and cultured for 72 h. For analysis of mucosal cell cytokine
secretion pieces of 1 cm
2 size were resected from the colon of mice
and cultured in RPMI complete medium for 24 h. The
supernatants were collected and cytokine testing was performed
by CBA analysis (BD Pharmingen) as previously described [38].
The secretion of IL-17 by PBT and LPT was determined using an
IL-17A specific ELISA (eBioscience).
Further analysis of cytokine secretion of living T cells was
performed using a TNF-a secretion assay (Miltenyi Biotec).
Human PBT were stimulated with anti-CD3/CD28 mAb in the
presence or absence of 100 mg/ml Gal-4. After 72 h cells were
restimulated for 1 h with PMA (10 ng/ml) and ionomycin (1 mg/
ml) (both from Sigma Aldrich) and the secreted TNF-a was bound
to the surface of the secreting cell, stained and detected by flow
cytometry. Additionally, T cells were stained with 1 mg/ml PI and
cells being positive for PI were excluded for further analysis.
Measurement of caspase activity
Measurement of caspase activity was previously described [9].
Briefly, PBT were incubated with the PE-labeled anti-caspase-3
Ab, the carboxyfluorescein-labeled caspase-8 inhibitor FAM-
LETD-fmk or caspase-9 inhibitor FAM-LEHD-fmk (Biocarta),
all binding irreversibly to activated caspases-3, -8 or -9. Cells were
analysed by flow cytometry and the increase of caspase activity was
determined in comparison to untreated cells.
Analysis of apoptosis
PBT and LPT were stimulated with anti-CD3/CD28 or -CD2,
respectively, in the presence of 0, 25, 50, 100 or 200 mg/ml Gal-4.
After 24 h of incubation with Gal-4 apoptosis was determined by
annexin-V staining, necrosis by PI staining. For investigation of
the apoptotic pathway T cells were stimulated with anti-CD3/
CD28 mAb and pre-incubated for 30 min with or without the
irreversible calpain-inhibitor Z-LLY-fmk (50 mM) (BioVision), the
extracellular Ca
2+ chelator EGTA (4 mM) and the intracellular
Ca
2+ chelator BAPTA-AM (30 mM) (both from Dojindo, Japan).
Afterwards, cells were cultured for 24 h in the presence or absence
of 100 mg/ml Gal-4 and apoptosis was detected by staining cells
with annexin V/PI followed by flow cytomeric analysis.
Assessment of mitochondrial membrane potential
Rhodamine123 staining was performed to measure the
mitochondrial membrane potential of PBT as previously described
[9]. After 3, 6, 12, 24, and 48 h fluorescence analysis was
performed by flow cytometry.
Animals
Female BALB/c mice, weighing 18-20 g, were purchased from
Charles River Laboratories (Wilmington, MA). All animals were
held in standard caging conditions and received standard rodent
chow and drinking water ad libitum. All animal experiments were
approved by the local institutional review board.
Treatment protocol
The animals received 5% DSS added to drinking water to induce
an acute colitis. The control group was treated with sterile isotonic
saline i.p., the second group received 1 mg/kg BW Gal-4 i.p. three
times a day. The treatment started with the giving of the DSS
drinking water. The animals were weighted daily and sacrificed
under anaesthesia (Rompun; Bayer, Leverkusen, Germany and
Ketavet; Pharmacia GmbH, Erlangen, Germany) after 8 days of
treatment. Blood samples were collected from the heart. The colon
was removed and measured followed by further analysis.
Determination of disease activity and histological
grading of colitis
A disease activity index (DAI), previously described by
Rachmilewitz [39], was determined by an investigator blinded to
the protocol according to the standard scoring system. A fecal
occult blood test (hemoCAREH, care diagnostica, Moellersdorf,
Austria) was used for haemocult screening. Colonic tissues were
removed for histological analysis and MPO activity by division of
the colon along. For histological grading the tissues were
embedded into paraffin and HE-stained. The sections were scored
blindly for histological evidence of inflammation with a scoring
system previously described. MPO activity was assessed as
previously described [18].
Detection of apoptosis
Apoptotic cells within the mucosa were detected by enzymatic
in situ labelling of DNA strand breaks using the TUNEL reaction.
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using the Apoptosis Detection Kit (R&D Systems). Apoptotic cells
were counted in three power fields on four slices of different
animals by an investigator blinded to the protocol.
Detection of proliferation
Proliferating cells in the colon were detected by injecting BrdU
(BD Pharmingen) i.p. 24 h before section. To visualize the
proliferating cells paraffin slides were incubated with biotinylated
anti-BrdU Ab followed by strepavidin-HRP and 3.39-Diamino-
benzidine as substrate. BrdU positive cells were counted in three
power fields on four slices of different animals by an investigator
blinded to the protocol.
Statistical analysis
Data are expressed as means6the standard deviation of the
means. Statistical analysis for significant differences was performed
by using analysis of variance, the Student’s t test for parametric
samples (GraphPad Prism, San Diego, CA).
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